U.S. markets open in 2 hours 20 minutes
  • S&P Futures

    4,398.50
    -34.50 (-0.78%)
     
  • Dow Futures

    34,617.00
    -126.00 (-0.36%)
     
  • Nasdaq Futures

    14,973.00
    -221.75 (-1.46%)
     
  • Russell 2000 Futures

    2,271.20
    -5.80 (-0.25%)
     
  • Crude Oil

    76.12
    +0.67 (+0.89%)
     
  • Gold

    1,733.50
    -18.50 (-1.06%)
     
  • Silver

    22.19
    -0.50 (-2.20%)
     
  • EUR/USD

    1.1684
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    21.08
    +3.33 (+18.76%)
     
  • GBP/USD

    1.3606
    -0.0098 (-0.71%)
     
  • USD/JPY

    111.4180
    +0.4400 (+0.40%)
     
  • BTC-USD

    41,923.20
    -1,816.39 (-4.15%)
     
  • CMC Crypto 200

    1,038.96
    -62.56 (-5.68%)
     
  • FTSE 100

    7,034.26
    -29.14 (-0.41%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

VANCOUVER, British Columbia, July 22, 2021--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

The live webcast of the earnings conference call will be available through a link that will be posted on AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more info, visit www.abcellera.com.

Source: AbCellera Biologics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005812/en/

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116